Defunct Company
Total Trials
6
As Lead Sponsor
5
As Collaborator
1
Total Enrollment
946
NCT00003715
Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma
Phase: Phase 2
Role: Lead Sponsor
Start: Dec 31, 1998
Completion: Not specified
NCT00257465
Trial of Autologous, Hapten-Modified Vaccine in Patients With Stage III or IV Melanoma
Phase: Phase 1/2
Start: Jun 30, 2005
Completion: Jun 30, 2008
NCT00298298
DNP-Modified Autologous Tumor Cell Vaccine for Resectable Non-Small Cell Lung Cancer
Start: Jan 31, 2006
Completion: Jan 31, 2014
NCT00660101
Trial of Autologous, Hapten-Modified Vaccine, OVAX, in Patients With Relapsed Stage III or IV Ovarian Cancer
Start: Jun 30, 2008
Completion: Jan 31, 2016
NCT00477906
M-Vax + Low Dose Interleukin-2 Versus Placebo Vaccine in Metastatic Melanoma in Patients With Stage IV Melanoma
Phase: Phase 3
Start: Jul 31, 2016
Completion: Jan 31, 2021
NCT04684823
The Impact of Patch Rx Technologies on Adherence to Vitamin and Trikafta Therapies in Patients With Cystic Fibrosis
Phase: N/A
Role: Collaborator
Start: Jan 15, 2021
Completion: Dec 27, 2021